CRYAB and breast carcinoma: Via structure-based molecular docking, a small compound, called NCI-41356, was identified that inhibits the interaction between HSPB5 and vascular endothelial growth factor VEGF165, which plays an important role in the development of breast cancer (Chen et al. 2014).